Crossject
Develops emergency medications delivered via a needle-free auto-injector platform.
ALCJ | PA
Overview
Corporate Details
- ISIN(s):
- FR0004178614 (+6 more)
- LEI:
- 969500W1VTFNL2D85A65
- Country:
- France
- Address:
- 6 Rue Pauline Kergomard, 21000 dijon
- Website:
- https://www.crossject.com/en
- Sector:
- Manufacturing
Description
Crossject is a specialty pharmaceutical company focused on developing and commercializing medications for life-threatening emergency situations. The company's core technology is ZENEO®, a proprietary, pre-filled, single-use needle-free auto-injector. This platform is designed to enable patients or untrained caregivers to rapidly, safely, and reliably administer emergency treatments. Crossject's product pipeline targets critical conditions such as epileptic seizures, acute adrenal crisis, and severe allergic reactions (anaphylaxis), aiming to improve patient outcomes by simplifying drug delivery in urgent scenarios.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-09-20 20:34 |
Crossject : Résultats semestriels 2022 - Franchissement d’étapes majeures sur …
|
French | 357.5 KB | ||
| 2022-09-19 18:29 |
Crossject : La phase opérationnelle de coopération entre la BARDA et Crossject …
|
French | 628.9 KB | ||
| 2022-09-15 18:45 |
Crossject : Intérêt de l’auto-injecteur ZENEO® pour une société pharmaceutique …
|
French | 621.9 KB | ||
| 2022-09-12 18:03 |
CROSSJECT : Utilisation sure rapide et efficace de ZENEO® Midazolam validée par…
|
French | 639.3 KB | ||
| 2022-09-07 18:18 |
Crossject : Information relative au nombre total de droits de vote et d’actions…
|
French | 648.8 KB | ||
| 2022-08-15 16:09 |
Crossject : Crossject obtient la certification ISO 13485
|
French | 634.7 KB | ||
| 2022-07-19 18:00 |
CROSSJECT : Etude clinique ZENEO® Midazolam : la phase des injections est termi…
|
French | 151.1 KB | ||
| 2022-07-06 18:00 |
Crossject : Vif succès de l’exercice des BSA
|
French | 126.2 KB | ||
| 2022-06-27 08:30 |
Crossject répond aux questions posées par les actionnaires individuels et inves…
|
French | 127.1 KB | ||
| 2022-06-20 08:52 |
Crossject s’adresse à ses actionnaires en vidéo suite à l’accord avec la BARDA …
|
French | 132.8 KB | ||
| 2022-06-18 13:13 |
CROSSJECT : Accord avec la BARDA sur ZENEO® Midazolam
|
French | 205.7 KB | ||
| 2022-06-18 13:13 |
CROSSJECT: Agreement with BARDA on ZENEO® Midazolam
|
English | 192.7 KB | ||
| 2022-06-09 18:53 |
Crossject : Descriptif du programme de rachat d’actions
|
French | 121.7 KB | ||
| 2022-06-08 18:15 |
Crossject : Crossject à l’écoute de ses actionnaires individuels et des investi…
|
French | 615.1 KB | ||
| 2022-05-24 18:27 |
CROSSJECT : Premières injections de ZENEO® Midazolam pour l’étude clinique de b…
|
French | 157.3 KB |
Automate Your Workflow. Get a real-time feed of all Crossject filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Crossject
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Crossject via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-24 | N/A | Other | Buy | 20,000 | N/A |
| 2024-06-14 | N/A | Other | Other | 10,979 | 20,289.19 EUR |
| 2024-06-06 | N/A | Other | Other | 1,058,617 | 1,956,324.22 EUR |
| 2024-06-06 | N/A | Other | Other | 16,106 | 29,763.89 EUR |
| 2024-06-06 | N/A | Other | Other | 10,275 | 18,988.20 EUR |
| 2024-06-06 | N/A | Other | Other | 10,074 | 18,616.75 EUR |
| 2024-06-06 | N/A | Other | Buy | 5,536 | 10,230.53 EUR |
| 2023-03-06 | N/A | Other | Other | 22,859 | 75,434.70 EUR |
Peer Companies
